Solid Tumor

The FDA granted accelerated approval to repotrectinib for the treatment of adults and children 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion.

Although an abundance of treatments exist for breast cancer, there are almost no options for screening patients for risk for recurrence or spread of early-stage breast cancer, representing a major unmet need in the field.

The number of cancer surgeries, chemotherapy treatments and radiation treatments declined dramatically during the first months of the COVID-19 pandemic, study findings published in JAMA Oncology showed.

Researchers from City of Hope have detailed results of preclinical studies designed to optimize the durability of chimeric antigen receptor T cells for advanced ovarian cancer.

In this video, Karen M. Winkfield, MD, PhD, discusses how the annual Chemotherapy Foundation Symposium “address[es] all cancers, across the board.”

Vascular endothelial growth factor and immune checkpoint inhibitors may help prevent brain metastases among patients with solid tumors, according to results from a systematic review and meta-analysis published in Neurology.

Intratumoral mRNA-2416, a lipid nanoparticle therapeutic agent expressing the wild-type human OX40L, appeared safe among a cohort of patients with locally advanced, recurrent or metastatic solid tumors, according to results of a phase 1/2 first-in-human study presented at the virtual American Association for Cancer Research Annual Meeting.

COM701, a novel first-in-class immune checkpoint inhibitor, demonstrated antitumor activity alone and in combination with nivolumab among patients with advanced solid tumors, according to results of a phase 1 study presented at the virtual American Association for Cancer Research Annual Meeting.

Novartis has reached an agreement with biopharmaceutical company TScan Therapeutics to develop new autologous T-cell receptor therapies for the treatment of solid tumors.